001     165985
005     20240229123217.0
024 7 _ |a pmid:33216838
|2 pmid
024 7 _ |a pmc:PMC7664984
|2 pmc
024 7 _ |a 10.3389/fonc.2020.575909
|2 doi
024 7 _ |a 10.3389/fonc.2020.575909
|2 doi
024 7 _ |a altmetric:93546415
|2 altmetric
037 _ _ |a DKFZ-2020-02524
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Rattay, Tim
|b 0
245 _ _ |a External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort.
260 _ _ |a Lausanne
|c 2020
|b Frontiers Media
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1607690788_17992
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Background: Acute skin toxicity is a common and usually transient side-effect of breast radiotherapy although, if sufficiently severe, it can affect breast cosmesis, aftercare costs and the patient's quality-of-life. The aim of this study was to develop predictive models for acute skin toxicity using published risk factors and externally validate the models in patients recruited into the prospective multi-center REQUITE (validating pREdictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve QUalITy of lifE in cancer survivors) study. Methods: Patient and treatment-related risk factors significantly associated with acute breast radiation toxicity on multivariate analysis were identified in the literature. These predictors were used to develop risk models for acute erythema and acute desquamation (skin loss) in three Radiogenomics Consortium cohorts of patients treated by breast-conserving surgery and whole breast external beam radiotherapy (n = 2,031). The models were externally validated in the REQUITE breast cancer cohort (n = 2,057). Results: The final risk model for acute erythema included BMI, breast size, hypo-fractionation, boost, tamoxifen use and smoking status. This model was validated in REQUITE with moderate discrimination (AUC 0.65), calibration and agreement between predicted and observed toxicity (Brier score 0.17). The risk model for acute desquamation, excluding the predictor tamoxifen use, failed to validate in the REQUITE cohort. Conclusions: While most published prediction research in the field has focused on model development, this study reports successful external validation of a predictive model using clinical risk factors for acute erythema following radiotherapy after breast-conserving surgery. This model retained discriminatory power but will benefit from further re-calibration. A similar model to predict acute desquamation failed to validate in the REQUITE cohort. Future improvements and more accurate predictions are expected through the addition of genetic markers and application of other modeling and machine learning techniques.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to PubMed,
700 1 _ |a Seibold, Petra
|0 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
|b 1
|u dkfz
700 1 _ |a Aguado-Barrera, Miguel E
|b 2
700 1 _ |a Altabas, Manuel
|b 3
700 1 _ |a Azria, David
|b 4
700 1 _ |a Barnett, Gillian C
|b 5
700 1 _ |a Bultijnck, Renée
|b 6
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 7
|u dkfz
700 1 _ |a Choudhury, Ananya
|b 8
700 1 _ |a Coles, Charlotte E
|b 9
700 1 _ |a Dunning, Alison M
|b 10
700 1 _ |a Elliott, Rebecca M
|b 11
700 1 _ |a Farcy Jacquet, Marie-Pierre
|b 12
700 1 _ |a Gutiérrez-Enríquez, Sara
|b 13
700 1 _ |a Johnson, Kerstie
|b 14
700 1 _ |a Müller, Anusha
|0 P:(DE-He78)55e70ca2adf894e09e6d90b39fe358e1
|b 15
|u dkfz
700 1 _ |a Post, Giselle
|b 16
700 1 _ |a Rancati, Tiziana
|b 17
700 1 _ |a Reyes, Victoria
|b 18
700 1 _ |a Rosenstein, Barry S
|b 19
700 1 _ |a De Ruysscher, Dirk
|b 20
700 1 _ |a de Santis, Maria C
|b 21
700 1 _ |a Sperk, Elena
|b 22
700 1 _ |a Stobart, Hilary
|b 23
700 1 _ |a Symonds, R Paul
|b 24
700 1 _ |a Taboada-Valladares, Begoña
|b 25
700 1 _ |a Vega, Ana
|b 26
700 1 _ |a Veldeman, Liv
|b 27
700 1 _ |a Webb, Adam J
|b 28
700 1 _ |a West, Catharine M
|b 29
700 1 _ |a Valdagni, Riccardo
|b 30
700 1 _ |a Talbot, Christopher J
|b 31
700 1 _ |a consortium, REQUITE
|b 32
|e Collaboration Author
700 1 _ |a Lievens, Yolande
|b 33
700 1 _ |a van Eijkeren, Marc
|b 34
700 1 _ |a Ost, Piet
|b 35
700 1 _ |a Fonteyne, Valérie
|b 36
700 1 _ |a Monten, Christel
|b 37
700 1 _ |a De Neve, Wilfried
|b 38
700 1 _ |a Peeters, Stephanie
|b 39
700 1 _ |a Haustermans, Karin
|b 40
700 1 _ |a Weltens, Caroline
|b 41
700 1 _ |a Defraene, Gilles
|b 42
700 1 _ |a Lambrecht, Maarten
|b 43
700 1 _ |a van Limberghen, Erik
|b 44
700 1 _ |a Briers, Erik
|b 45
700 1 _ |a Bourgier, Celine
|b 46
700 1 _ |a Brengues, Muriel
|b 47
700 1 _ |a Draghici, Roxana
|b 48
700 1 _ |a Bons, Francoise
|b 49
700 1 _ |a Blaschke, Thomas
|b 50
700 1 _ |a Weiß, Christian
|b 51
700 1 _ |a Helmbold, Irmgard
|b 52
700 1 _ |a Weißenberger, Christian
|b 53
700 1 _ |a Stegmaier, Petra
|b 54
700 1 _ |a Claßen, Johannes
|b 55
700 1 _ |a Giesche, Ulrich
|b 56
700 1 _ |a Sautter-Bihl, Marie-Luise
|b 57
700 1 _ |a Neu, Burkhard
|b 58
700 1 _ |a Schnabel, Thomas
|b 59
700 1 _ |a Ehmann, Michael
|b 60
700 1 _ |a Gauter-Fleckenstein, Benjamin
|b 61
700 1 _ |a Herskind, Carsten
|b 62
700 1 _ |a Veldwijk, Marlon
|b 63
700 1 _ |a Schäfer, Jörg
|b 64
700 1 _ |a Giandini, Tommaso
|b 65
700 1 _ |a Franceschini, Marzia
|b 66
700 1 _ |a Sangalli, Claudia
|b 67
700 1 _ |a Avuzzi, Barbara
|b 68
700 1 _ |a Morlino, Sara
|b 69
700 1 _ |a Lozza, Laura
|b 70
700 1 _ |a Pietro, Gabriele
|b 71
700 1 _ |a Delmastro, Elena
|b 72
700 1 _ |a Garibaldi, Elisabetta
|b 73
700 1 _ |a Cicchetti, Alessandro
|b 74
700 1 _ |a Vanneste, Ben
|b 75
700 1 _ |a Piqué-Leiva, Bibiana
|b 76
700 1 _ |a Molla, Meritxel
|b 77
700 1 _ |a Giraldo, Alexandra
|b 78
700 1 _ |a Ramos, Monica
|b 79
700 1 _ |a Lobato-Busto, Ramon
|b 80
700 1 _ |a Sosa-Fajardo, Paloma
|b 81
700 1 _ |a Moya, Laura Torrado
|b 82
700 1 _ |a Dominguez-Rios, Isabel
|b 83
700 1 _ |a Fajardo-Paneque, Irene
|b 84
700 1 _ |a Calvo-Crespo, Patricia
|b 85
700 1 _ |a Carballo, Ana
|b 86
700 1 _ |a Peleteiro, Paula
|b 87
700 1 _ |a Olivia-Fuentes-Rios
|b 88
700 1 _ |a Gomez-Caamano, Antonio
|b 89
700 1 _ |a Harrop, Victoria
|b 90
700 1 _ |a Payne, Debbie
|b 91
700 1 _ |a Keni, Manjusha
|b 92
700 1 _ |a Lavers, Samuel
|b 93
700 1 _ |a Wright, Simon
|b 94
700 1 _ |a Thiagarajan, Sridhar
|b 95
700 1 _ |a Aznar-Garcia, Luis
|b 96
700 1 _ |a Kancherla, Kiran
|b 97
700 1 _ |a Kent, Christopher
|b 98
700 1 _ |a Vasanthan, Subramaniam
|b 99
700 1 _ |a Appleton, Donna
|b 100
700 1 _ |a Kaushik, Monika
|b 101
700 1 _ |a Kenny, Frances
|b 102
700 1 _ |a Khout, Hazem
|b 103
700 1 _ |a Krupa, Jaroslaw
|b 104
700 1 _ |a Lambert, Kelly V
|b 105
700 1 _ |a Pilgrim, Simon
|b 106
700 1 _ |a Shokuhi, Sheila
|b 107
700 1 _ |a Valassiadou, Kalliope
|b 108
700 1 _ |a Bioangiu, Ion
|b 109
700 1 _ |a Sampson, Kufre
|b 110
700 1 _ |a Osman, Ahmed
|b 111
700 1 _ |a Faivre-Finn, Corinne
|b 112
700 1 _ |a Foweraker, Karen
|b 113
700 1 _ |a Pascoe, Abigail
|b 114
700 1 _ |a Esler, Claire P
|b 115
700 1 _ |a Ward, Tim
|b 116
700 1 _ |a Higginson, Daniel S
|b 117
700 1 _ |a Stock, Richard G
|b 118
700 1 _ |a Green, Sheryl
|b 119
773 _ _ |a 10.3389/fonc.2020.575909
|g Vol. 10
|0 PERI:(DE-600)2649216-7
|p 575909
|t Frontiers in oncology
|v 10
|y 2020
|x 2234-943X
909 C O |o oai:inrepo02.dkfz.de:165985
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)55e70ca2adf894e09e6d90b39fe358e1
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT ONCOL : 2018
|d 2020-09-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-09-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-09-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-09-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2020-09-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2020-09-06
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2020-09-06
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-09-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-09-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-09-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2020-09-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-09-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-09-06
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2020-09-06
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-09-06
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-09-06
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21